Immunicon Achieves Endpoints in its Pivotal Clinical Trial in Metastatic Colorectal Cancer (FinanzNachrichten)
Immunicon Corporation ( Nachrichten ) (NASDAQ-GM:IMMC) announced today that the Company met the primary and secondary endpoints associated with its pivotal clinical trial in metastatic colorectal cancer.

Glivec Receives Additional EU Approvals For Use In Treating A Rapidly Progressive Form Of Leukemia And A Hard-to-treat (Medical News Today)
Novartis has received additional European Union approvals for Glivec (imatinib) to help patients with a rapidly progressive form of leukemia as well as a hard-to-treat solid cancer tumor. Both are rare and potentially life-threatening diseases with few, if any, approved treatments that have resulted in poor long-term outcomes. [click link for full article]

Drug Safety Overhaul Is Urged (KTLA 5)
The FDA spends far more time on approvals than on follow-ups, a review finds. Calls for reform include warning labels and limits on ads.